CN112533640B - 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向 - Google Patents

利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向 Download PDF

Info

Publication number
CN112533640B
CN112533640B CN201980030270.8A CN201980030270A CN112533640B CN 112533640 B CN112533640 B CN 112533640B CN 201980030270 A CN201980030270 A CN 201980030270A CN 112533640 B CN112533640 B CN 112533640B
Authority
CN
China
Prior art keywords
tumor
mel
dkla
melittin
anticancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980030270.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112533640A (zh
Inventor
裴玹秀
李澯珠
郑镇玹
李睹夏
金正东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shuanghai Life Science Co ltd
Original Assignee
Shuanghai Life Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shuanghai Life Science Co ltd filed Critical Shuanghai Life Science Co ltd
Publication of CN112533640A publication Critical patent/CN112533640A/zh
Application granted granted Critical
Publication of CN112533640B publication Critical patent/CN112533640B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980030270.8A 2018-05-04 2019-05-07 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向 Active CN112533640B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0051800 2018-05-04
KR20180051800 2018-05-04
PCT/KR2019/005438 WO2019212324A1 (ko) 2018-05-04 2019-05-07 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화

Publications (2)

Publication Number Publication Date
CN112533640A CN112533640A (zh) 2021-03-19
CN112533640B true CN112533640B (zh) 2025-02-28

Family

ID=68386643

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980030270.8A Active CN112533640B (zh) 2018-05-04 2019-05-07 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向

Country Status (8)

Country Link
US (1) US11484601B2 (https=)
EP (1) EP3789041A4 (https=)
JP (1) JP7234349B2 (https=)
KR (1) KR102250412B1 (https=)
CN (1) CN112533640B (https=)
AU (1) AU2019264092B2 (https=)
CA (1) CA3099434C (https=)
WO (1) WO2019212324A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240009269A1 (en) * 2020-11-20 2024-01-11 The Johns Hopkins University Membrane-active peptides and methods for reversible blood- brain barrier opening
CA3153060A1 (en) * 2021-05-07 2022-11-07 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
US20220354957A1 (en) * 2021-05-07 2022-11-10 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
CN113336828B (zh) * 2021-06-30 2022-03-25 中国海洋大学 抗菌肽yhx-3及其组合物和应用
CN114437193A (zh) * 2022-01-29 2022-05-06 陕西未来多肽生物科技有限公司 一种金-蜂毒肽纳米杂化物及其应用
KR20230144960A (ko) * 2022-04-07 2023-10-17 트윈피그바이오랩(주) 신규 펩타이드 기반 면역항암제
WO2023204329A1 (ko) * 2022-04-22 2023-10-26 트윈피그바이오랩(주) 신규 펩타이드 기반 면역항암제
CN115317622B (zh) * 2022-08-12 2025-08-22 青岛科技大学 一种抗肿瘤多肽偶联药物的制备及其应用
CN116589555B (zh) * 2023-03-31 2024-02-06 广东医科大学 一种细胞穿梭肽及其应用
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
KR20250091126A (ko) * 2023-12-12 2025-06-20 트윈피그바이오랩(주) 신규 펩타이드를 유효성분으로 포함하는 항암제와의 병용투여를 위한 항암 조성물
CN120053399A (zh) * 2025-02-27 2025-05-30 滁州学院 一种蜂毒肽靶向制剂及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
BRPI0923283A2 (pt) 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
KR20110117789A (ko) 2010-04-22 2011-10-28 대한민국(농촌진흥청장) 멜리틴을 함유하는 동맥경화 치료용 조성물
KR20110117788A (ko) 2010-04-22 2011-10-28 대한민국(농촌진흥청장) 멜리틴을 포함하는 섬유아세포-유사-활막세포의 활성을 억제하는 조성물
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
KR101935095B1 (ko) * 2015-07-31 2019-01-04 이화여자대학교 산학협력단 신규한 세포투과성 펩타이드
CN106699896B (zh) * 2016-12-05 2020-06-05 华中科技大学同济医学院附属协和医院 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用
KR102073273B1 (ko) 2017-08-23 2020-03-02 (주) 레느스랩 멜리틴을 포함하는 m2형 종양관련 대식세포 제거용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Development of melittin-based anti-cancer drug for targeting tumor-associated macrophages;Chanju Lee et al.;THE JOURNAL OF IMMUNOLOGY;20180501;第200卷(第1期);56.22 *

Also Published As

Publication number Publication date
US20210244823A1 (en) 2021-08-12
CA3099434A1 (en) 2019-11-04
AU2019264092A8 (en) 2021-01-07
WO2019212324A1 (ko) 2019-11-07
KR102250412B1 (ko) 2021-05-17
US11484601B2 (en) 2022-11-01
EP3789041A4 (en) 2022-07-13
CN112533640A (zh) 2021-03-19
EP3789041A1 (en) 2021-03-10
KR20190127609A (ko) 2019-11-13
AU2019264092B2 (en) 2024-02-15
CA3099434C (en) 2023-09-05
AU2019264092A1 (en) 2020-12-24
JP2021526548A (ja) 2021-10-07
JP7234349B2 (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
CN112533640B (zh) 利用基于蜂毒肽的细胞凋亡诱导肽的m2型肿瘤相关巨噬细胞的靶向
US12269902B2 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
JP7359700B2 (ja) Ｃｄ３８抗体薬物コンジュゲート
JP6748155B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
CN109513010B (zh) 肿瘤细胞特异性响应的自组装药物纳米缀合物
WO2018079740A1 (ja) 癌の治療及び／又は予防用医薬組成物
KR102224965B1 (ko) 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
US20240156971A1 (en) Methods and sortilin binding conjugate compounds for targeting cancer stem cells
CN106659764B (zh) 环状鞘脂激活蛋白原肽及其用途
US20210139608A1 (en) Bio-responsive adhesive antibody delivery platform for immunotherapy and preparation method thereof
KR102831503B1 (ko) 암 예방 또는 치료를 위한 알부민 결합 전구약물, 이를 포함하는 약학 조성물
EP4512410A1 (en) Novel-peptide-based anticancer immunotherapeutic agent
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant